NTL Executive Committee member Kimberly Dougherty talks about Essure Posted on July 31, 2018 by Andrew Findley We are pleased to advise that recently Bayer announced by the end of December, they would be discontinuing the sale of Essure®, a permanent contraceptive. Many women decided to go with the Essure® implant because it was marketed as a device that does not require surgery. Sadly, thousands of women have had to have extensive surgery to remove the device as a result of significant, debilitating injuries that the device causes. The removal of the device from the market is a major step in the right direction for the women who have been hurt by this device. The FDA ordered in April that the sale and distribution of Essure® be restricted and threatened to invoke criminal penalties if Bayer didn’t tell patients about the serious health risks associated with the product. The FDA stated, “For women who have received an Essure® implant, the postmarket safety of Essure® will continue to be a top priority for the FDA. We expect Bayer to meet its postmarket obligations concerning this device.” Managing Partner Kim Dougherty and others at Andrus Wagstaff, PC have been working tirelessly to hold Bayer accountable for the pain and suffering so many women are suffering. Ms. Dougherty was appointed to the Executive Committee of the JCCP for the Essure® litigation pending in Oakland, California. If you would like to reach out to her to discuss Essure® and any potential cases you may have you can reach her at 508-230-2333 or at email@example.com. You can also read more about Essure® on our website.